Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Research output: Contribution to journalComment/debatepeer-review

Abstract

Objective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome. Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication. Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects. Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.

Original languageEnglish (US)
Pages (from-to)547-551
Number of pages5
JournalNeuropsychiatric Disease and Treatment
Volume5
Issue number1
DOIs
StatePublished - 2009
Externally publishedYes

Keywords

  • Epilepsy
  • Epileptic encephalopathy
  • Lennox-gastaut syndrome
  • Pediatric
  • Rufinamide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide'. Together they form a unique fingerprint.

Cite this